Prostate brachytherapy has come of age: A review of the technique and results

BJU International

Volumn 89, Issue 3, 2002, Pages 241-249

  Langley, Stephen E M ^a   Laing, R ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD 198; IODINE 125; IRIDIUM; PALLADIUM 103; RADIUM;

BRACHYTHERAPY; DOSE RESPONSE; DOSIMETRY; HALF LIFE TIME; HISTORY; HUMAN; IMPLANT; IMPLANTATION; IONIZING RADIATION; LONG TERM CARE; MORBIDITY; NECROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SEXUAL FUNCTION; SOLID TUMOR; STRESS INCONTINENCE; TARGET ORGAN; TECHNIQUE; TRANSURETHRAL RESECTION; URINE INCONTINENCE;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 0036181750     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.01610.x     Document Type: Review

References (80)

1. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer
2. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire
3. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer
4. Combined interstitial and external irradiation for prostate cancer
5. 125 in the treatment of prostatic cancer
6. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localised prostatic cancer
7. Temporary iridium-192 impIant in the management of carcinoma of the prostate
8. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography
9. Spacing nomogram for interstitial implants of I-125 seeds
10. Transperineal ultrasound guided palladium-103 brachytherapy for prostate carcinoma
11. Value of computed tomography in interstitial 125-I brachytherapy of prostatic carcinoma
12. Improved technique for prostate seed implantation. Combined ultrasound and fluoroscopic guidance
13. A new device to stabilise templates for transperineal I-125 implants
14. A modified technique allowing interactive ultrasound-guided 3-dimensional transperineal prostate implantation
15. Dose selection for prostate cancer patients based on dose comparison and dose-response studies
16. Superior sulcus tumours; treatment selection and results for 85 patients without metastasis at presentation
17. Stage IIB carcinoma of the cervix managed with radiation therapy: An analysis of prognostic factors
18. Permanent implants using Au198, 103Pd and 125I. Radiobiological considerations based on a linear quadratic model
19. Radiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model
20. Brachytherapy for clinically localised prostate cancer: Results at 7- and 8-year follow up
21. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high dose rate brachytherapy
22. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I, based on radiobiological effectiveness and dosimetry
23. Isotope selection for patients undergoing prostate brachytherapy
24. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
25. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer. Technical concepts in planning, operative technique, and evaluation
26. Prostate seed implant quality assessment using MR and CT image fusion
27. Palladium-103 brachytherapy for prostate cancer
28. Consensus statement: Guidelines for PSA following radiation therapy
29. Transient elevation of serum prostate specific antigen following 125I-103Pd brachytherapy for localised prostate cancer
30. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
31. Serum PSA after anatomical radical prostatectomy
32. The case for external beam treatment of early-stage prostate cancer
33. Retrospective comparison of radical retropubic prostatectomy and 125 iodine brachytherapy for localized prostate cancer
34. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate
35. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray extarnal beam irradiation in the treatment of patients with clinically localised, low to high grade Gleason prostate carcinoma
36. Actuarial disease free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance
37. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
38. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer
39. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumours in 2222 patients: Results from a single practice
40. 10 Year biochemical (PSA) control of prostate cancer with 125I brachytherapy
41. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years observed follow up
42. The role of external beam radiotherapy with 125I/103Pd brachytherapy for prostate cancer
43. Brachytherapy
44. Neoadjuvant ablation combined with external-beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer
45. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
46. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation
47. Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer
48. Detailed preliminary analysis of I-125 implantation for localized prostate cancer using percutaneous approach
49. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy
50. Post implant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution
51. A dose-response study for I-125 prostate implants
52. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate
53. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications
54. Biochemical and disease free survival following I-125 prostate implantation
55. Short-term freedom from disease progression after I-125 prostate implantation
56. Tumour control and morbidity following I-125 prostate implantation for stage T1/T2 prostatic carcinoma
57. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland
58. Urinary morbidity with a modified peripheral loading technique of transperineal 125, I prostate implantation
59. Temporal resolution of urinary morbidity following prostate brachytherapy
60. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma
61. Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T1-T2 prostate cancer
62. Neoadjuvant hormonal down-sizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation
63. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate
64. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer
65. Improved survival in patients with clinically advanced prostate cancer treated with radiotherapy and goserelin
66. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer
67. Prostate specific antigen findings and biopsy results following interactive ultrasound-guided transperineal brachytherapy early stage prostate carcinoma
68. Brachytherapy and organ preservation in the management of carcinoma of the prostate
69. Short term morbidity from CT-planned transperineal I-125 prostate implants
70. Quality of life after permanent prostate implant
71. Comparison of the 5 year outcome and morbidity of 3-dimensional conformal radiotherapy versus transperineal permanent Iodine-125 implantation for early-stage prostate cancer
72. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction
73. Risk factors for impotence in patients with carcinoma of the prostate treated with 3-dimensional conformal radiation therapy
74. Prostate brachytherapy; treatment strategies
75. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer
76. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: A longitudinal multi-varied quality of life analysis from the cancer of the prostate strategic research endeavour
77. Quality of life outcomes after brachytherapy for early stage prostate cancer
78. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localised prostate cancer
79. Long term treatment related complications of brachytherapy for early prostate cancer: A survey of treated patients
80. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localised prostate cancer